Invasive Group B Streptococcal Disease in Non-pregnant Adults: A Review with Emphasis on Skin and Soft-tissue Infections by Sendi, P. et al.
Invasive Group B Streptococcal
Disease in Non-pregnant Adults
A Review with Emphasis on Skin and Soft-tissue Infections
P. Sendi, L. Johansson, A. Norrby-Teglund
Abstract
Streptococcus agalactiae, commonly referred as group B
Streptococcus (GBS), is a major cause of neonatal sepsis and
infections in pregnant women. However, the number of
invasive infections in non-pregnant adults is growing.
Elderly patients and those with chronic underlying condi-
tions, such as diabetes mellitus or compromised immune
defence, are at increased risk of invasion. The spectrum of
clinical manifestations is broad and includes necrotizing
fasciitis and toxic shock syndrome. Although, primary
bacteremia and skin and soft-tissue infections are the most
frequently reported diagnosis. This article reviews the
epidemiology, pathogenesis and treatment of invasive GBS
disease in non-pregnant adults, with an emphasis on skin
and soft-tissue infections.
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Introduction
Streptococcus agalactiae is the only streptococcal species
that carries the Lancefield group B antigen, hence its
alternative designation as group B Streptococcus (GBS).
It is a leading cause of morbidity and mortality in
neonates and pregnant women. In many industrialized
countries, recommendations for diagnosing maternal
GBS colonization and administering intrapartum anti-
microbial prophylaxis have been introduced, leading to
a significance decrease in these infections [1]. However,
the rate of invasive GBS disease in non-pregnant adults
continues to climb [2]. Elderly persons and those with
underlying diseases – two expanding segments of the
population – are at increased risk. This article reviews
the epidemiology of invasive GBS disease in non-preg-
nant adults, describes clinical, immunological and bac-
terial perspectives of its pathogenesis, and discusses
treatment concepts for this condition. Emphasis is
placed on skin and soft-tissue infections, which are
among the most frequently reported clinical problems.
Epidemiology
Incidence of Invasive Group B Streptococcal
Disease
In the early 1990s, three large surveillance studies in the
United States reported a significant increase over the
previous two decades in the annual incidence of invasive
GBS disease (defined as isolation of S. agalactiae from a
normally sterile site [3]) among non-pregnant adults. The
rates had reached 2.4–4.4 cases per 100,000 population
[4–6]. Thereafter, several reports revealed an increase in
incidence of both invasive diseases and bacteremia per
1000 hospital admissions [2, 7]. Recent studies have re-
ported an annual incidence of invasive GBS disease of
0.96 (Spain) or an incidence of GBS bacteremia of 0.136
(Hong Kong), 0.30 (Taiwan) and 0.42 (Spain) cases per
1000 hospital admissions, which also illustrate regional
differences [7–9]. This trend can be partly explained by a
growing number of patients with predisposing factors, in
particular, chronic medical conditions.
Relapsing Infections
Approximately 5% of non-pregnant adults will have at
least a second episode of GBS disease. In the study by
Harrison et al. [10] the interval between the first and second
episode averaged 13 weeks if the bacteremia was caused by
the same strain and 43 weeks if it was caused by a different
strain. In this study, all infections occurred in patients with
predisposing conditions, and cellulitis was the most fre-
quent recurrent clinical manifestation.
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Predisposing Conditions and Risk Factors
The vast majority of patients with GBS infections have at
least one predisposing condition. Important risk factors
and their calculated incidence rates are presented in ta-
ble 1. Older age (> 65 years), diabetes mellitus, cancer
and compromised immunity are recognized to increase
the risk of acquiring invasive GBS disease [2, 4, 6, 11].
Venous oedema and/or lymphoedema have been deter-
mined as risk factors for relapsing erysipelas/cellulitis of
the lower leg [12]. However, in a retrospective study
analysing 71 patients suffering from GBS skin and soft-
tissue infections [13], 17 (24%) had no obvious underlying
disease. This percentage is higher than those previously
reported, ranging between 0–8% [2, 4, 6, 7, 14–17]. Nev-
ertheless, it emphasizes that GBS is not exclusively
affecting risk groups.
Since, like all patients, GBS-colonized individuals are
exposed to various instrumentation techniques (e.g. uri-
nary catheter, sigmoidoscopy), this iatrogenic factor may
be contributing to the incidence rate [18, 19]. In one-
quarter (17–30%) of the cases, invasive GBS disease oc-
curs ‡ 48 hours after admission to a hospital [6, 11, 20].
Nosocomial infection may therefore arise from pre-exist-
ing colonized skin or mucosal surfaces.
Prevalence of GBS Colonization
In colonized individuals, GBS is generally isolated from
cultures of the rectum, perianal area, vagina, cervix and
urethra or, less commonly, from cultures of the skin and
pharynx. The colonization rate ranges from 20 to 35%
[21–26]. The prevalence is higher among sexually active
persons and those who have multiple sex partners, sug-
gesting that acquisition of this microorganism is caused by
intimate contact [23, 27]. This is also supported by a study
showing identical strains in 86% of co-colonized sex
partners [21].
Serotype Distribution
GBS expresses a polysaccharide antigen on its surface that
is used for serotype identification. To date, nine serotypes
have been identified: Ia, Ib and II–VIII [28]. Character-
ization of a GBS strain also includes the presence of
surface proteins. The C-protein complex, which consists of
two independently expressed components (the a- and
b-antigen), is among the best-studied of these surface
proteins.
Most of the epidemiological data on GBS serotypes
have been collected from strains causing invasive disease.
In non-pregnant adults, almost 70% of the invasive cases
have been attributed to serotypes Ia, III and V [29–31].
These three serotypes also dominated in a study analysing
colonizing strains in healthy elderly persons [26]. C-protein
antigens are found in 40–60% of clinical isolates, mostly in
strains with serotype Ia, Ib and II [28, 32]. However, the
serotype distribution has shifted somewhat during the past
few years [33]. Pregnant Japanese women were found to be
predominantly colonized with serotypes VI and VIII [34],
whereas invasive disease was being increasingly caused by
serotype VIII in a Danish study [35]. Whether this differ-
ence is due to geographic predominance or due to the type
of infection remains to be determined. However, the
serotype distribution of both invasive and colonizing
Table 1
Underlying conditions associated with an increased risk for acquiring GBS infections in non-pregnant adults.





Risk calculation (95% CI)
Relative risk Odds ratio
Retrospective population-based surveillance,
non-pregnant adults, 56 [4]
Diabetes mellitus 13.7 10.5 (7.8–14.4) –
Cancer 21.3 16.4 (11.5–23.3) –
Case-control study, non-pregnant adults, 219 cases
and 645 hospital-matched controls [11]
Diabetes mellitusb – – 3.0 (1.9–4.7)
Breast cancerb – – 4.0 (1.6–9.8)
Liver cirrhosisb – – 9.7 (3.5–26.9)
Neurogenic bladderb – – 4.6 (1.4–15.1)
Decubitus ulcerb – – 4.0 (1.6–9.8)
Strokeb – – 3.5 (1.9–6.4)
Prospective population-based surveillance,
non-pregnant adults, 137 [6]
Diabetes mellitus (age 20–40) 20 30 (11–79) –
HIV (age 30–49) 54 30 (11–78) –
Active bacterial core surveillancec Age > 65 25.6 – –
The surveillance areas represented 27,350,255 persons [3]
Active surveillance, non-pregnant adults, 867 cases
including 84 nursing home residents [134]
Nursing home residents age ‡ 65 – 4.1 (2.6–6.7)d
aAnnual incidence of invasive GBS infection per 100,000 population; bMultivariate analysis [11] adjusted for age, diabetes mellitus, breast
cancer, liver cirrhosis, neurogenic bladder, decubitus ulcer, stroke, congestive heart failure, dementia, incontinence, gastrointestinal
bleeding, alcoholism and prostate cancer; cCDC = Centers for Disease Control (USA); dCompared to selected community residents (age ‡ 65)
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strains is continuously evolving and demonstrates not only
regional but also temporal variation.
Macrolide- and Clindamycin-resistant Strains
There is significant and rising resistance to erythromycin
and clindamycin in both invasive and colonizing strains
[36]. Reported frequencies range from 7 to 16% and 3 to
9%, respectively [36, 37], although there are geographic
variations in resistance rates and prevalence of resistance
mechanisms. High rates of erythromycin and clindamycin
resistance have, however, only been rarely reported: in
one study testing 200 GBS isolates collected from vaginal/
rectal specimens [38], the resistance rate was 54% and
33%, respectively.
Among erythromycin-resistant isolates, several stud-
ies have reported serotype V as the most frequent sero-
type [39–43].
Challenges in Detecting GBS
Detailed routine diagnostic methods have been described
elsewhere and are beyond the scope of this review [44, 45].
However, clinicians should be aware that apart from the
commonly known phenotype with a narrow zone of
haemolysis on a blood agar plate, an unknown percentage
of the strains are either non-hemolytic or hyperhemolytic.
Non-haemolytic strains are non-pigmented, while hyper-
hemolytic strains are hyperpigmented [46]. Non-hemolytic
strains can be missed when strains are not screened for the
group B antigen. Furthermore, in screening procedures
for carrier status, low colonization levels, the presence of
other organisms (e.g. in a vaginal culture) and low test
sensitivity of the commercial assays pose problems in
identifying GBS. Therefore, the detection of GBS isolates
and the interpretation of culture results, both from colo-
nized individuals and patients suffering from invasive
disease, require a good collaboration between clinicians,
microbiologists and laboratory technicians.
Pathogenesis — the Clinical Perspective
According to the traditional concept, a clone of GBS is
entering normally sterile sites such as blood or cerebro-
spinal fluid after pre-existing or new colonization of the
host [47]. This model is supported by two recently pub-
lished case reports, showing identical strains isolated from
the vagina and the blood [48, 49].
The integrity and functionality of the mucosa and skin
represent the first line of host defence. Alteration of these
barriers allows the pathogen to escape from its reservoir
and cause invasive disease. Chronic medical conditions
typically known to be associated with skin alterations (e.g.
diabetes mellitus, peripheral vascular diseases, pressure
ulcers) or mucosal lesions (e.g. ulcer disease, HIV)
enhance the risk of invasive disease. Lymphatic or vas-
cular insufficiency, a history of radiation therapy or
chronic dermatological diseases are often present in skin
and soft-tissue infections [12, 49, 50]. As a typical example
of such a predisposing constellation to GBS infection, arm
and chest wall cellulitis have been reported in patients
with a history of breast cancer that has included surgical
and radiation therapy [6, 11, 48].
In relapsing diseases, focal infections such as endo-
carditis or osteomyelitis that may have been unrecognized
during the fist episode must be excluded [10]. Persistent
gastrointestinal or genitourinary carriage of a certain GBS
strain to which the host is susceptible (due to the patho-
gen’s virulence, or to the host’s immune status, or both)
may serve as a reservoir for relapsing invasive diseases
[48, 49]. Another possibility includes repetitive acquisition
of matching strains from intimate contact with a GBS
carrier. Bacterial persistence at the local site of infection
has been also speculated as a cause of recurrent skin and
soft-tissue infections [49]. In relapsing cellulitis, often
observed as a chronic complication after surgery, lym-
phatic tissue is altered and may lead to locally impaired
immune responses and insufficient bacterial clearance [12,
48, 51]. The observation of intracellular persistence in host
cells could also help to explain relapsing infections;
through this strategy, bacteria may escape common
extracellular immunological mechanisms as well as bac-
tericidal concentrations of antibiotic. Intracellular persis-
tence in non-professional phagocytes and in macrophages
has been shown in patient material with Staphylococcus
aureus [52] and Group A Streptococcus (GAS) [53]
infections, respectively.
Pathogenesis — the Immunological Perspective
The role of type-specific anti-GBS antibodies has been
primarily investigated in neonates and pregnant women.
Serum analyses of neonates (and their mothers) suffering
from systemic GBS serotype III infection have shown low
titres of type-specific antibodies directed against the cap-
sular polysaccharide (CPS) [54]. Clinical data to confirm the
hypothesis that type-specific antibodies may play an
important role in protecting non-pregnant adults from
invasive disease are sparse. Several studies have tested GBS
conjugate vaccines in healthy young adults and investigated
the functional activity and the concentration of the induced
antibodies [55–57]. They showed a significant positive cor-
relation between the concentration of CPS-specific anti-
body in the serum and opsonophagocytic activity.
Functional assays in elderly persons may partially
explain why this group is more susceptible to invasive
GBS disease. In a cross-sectional study with healthy el-
derly people [58], impaired GBS killing was associated
with a low concentration of CPS-specific antibodies [58].
The addition of pooled sera from young adults vaccinated
against type V GBS improved impaired neutrophil-med-
iated phagocytosis. Similarly, type V vaccination of heal-
thy elderly adults induced normal, functional antibodies
that promoted opsonophagocytic killing in vitro [59]. Ta-
ken together, these data suggest that CPS-specific anti-
bodies may play an important role in the immune defence
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of non-pregnant adults, although the clinical significance
of these results is difficult to assess. They also indicate that
due to limitations of factors other than immunoglobulins
in the host defence of the elderly, higher concentrations of
CPS-specific antibodies might be required to confer pro-
tection [47].
Similar conclusions can be drawn from studies in
diabetics, who are generally more prone to bacterial
infections. In assays using serum samples from persons
with insulin-dependent diabetes, poor opsonophagocyto-
sis to type II GBS improved following the addition of
CPS-specific antibodies [60]. Furthermore, neutrophils
obtained from elderly adults with type 2 diabetes showed
diminished superoxide production during hyperglycaemia
when stimulated with GBS type III. Improvement of the
oxidative burst was shown in the presence of a higher
CPS-specific IgG concentration [61].
Pathogenesis — the Bacterial Perspective
Detailed elucidation of the bacterial pathogenesis in hu-
mans poses several problems. GBS adapts to its host
during the process of colonization and expresses host-
specific surface proteins, some of which are only
expressed in the host and not in laboratory cultures.
Nevertheless, much research effort has been successfully
devoted to pathomechanisms of GBS diseases and has
identified a large number of important bacterial compo-
nents involved in adhesion, invasion, avoiding immune
clearance and causing inflammation (schematically in
figure 1). Several of these bacterial features occur via a
‘two-component regulatory system’. One component (e.g.
a sensor protein) is responsible for detecting and com-
municating the external stimuli, while the other compo-
nent (e.g. regulator protein) will react to those signals by
activating or repressing specific genes, leading to the
appropriate bacterial functions [62]. This system has been
recognized as a bacterial strategy to overcome environ-
mental stress factors, such as pH, temperature and
osmolarity [63], but also to adhere to host cells [64, 65]
and to express virulence factors [66].
Adhesion and Invasion
GBS interacts with extracellular matrix components of
eukaryotic host cells, such as fibronectin, fibrinogen, lam-
inin and cytokeratin 8. Several GBS surface-associated
factors have been implicated in the adhesion process (Fig-
ure 1). Once adhered, GBS is able to invade eukaryotic
cells, such as fibroblasts, endothelial and epithelial cells,
thus promoting bacterial penetration of host cellular bar-
riers, such as the blood-brain barrier [67], chorioamniotic
membranes [68] or barriers in the respiratory tract [69].
Avoidance of Immune Clearance
Apart from adaptation to environmental stress factors,
GBS displays several functions that provide protection
against killing by the host’s immune system. On mucosal
surfaces, GBS binds the Fc fragment of IgA via a surface-
associated protein complex (b-antigen of protein-C) [70]
and thus inhibits interaction of IgA with Fc receptors ex-
pressed on neutrophils, eosinophils or macrophages [71].
GBS possesses also several mechanisms to resist op-
sonophagocytosis. Sialic acid, a component of the capsule,
Figure 1. Schematic overview of GBS factors involved in adhesion, invasion, avoidance of immune clearance and virulence. The list of bacterial
features shown is not exhaustive and additional findings are being continuously reported in the literature. LTA: lipoteichoic acid; CPS: capsular
polysaccharide antigen, Fbs: fibrinogen-binding protein; Lmb: laminin-binding protein; BibA: B Streptococcus immunogenic bacterial adhesion.
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prevents deposition of active C3b, and thus its function as
an opsonin [72]. C5a, another important factor of the
complement system that acts as a chemotaxin for neutro-
phils, can also be inactivated by a surface-bound strepto-
coccal protease, namely C5a peptidase [73]. Other factors
that endow GBS with resistance to phagocytic killing by
neutrophils includes its penicillin-binding protein 1a, me-
talloproteases and superoxide dismutases (Figure 1) [74,
75]. Further strategies that have been suggested for how the
microorganism avoids opsonization by antibodies include
antigenic variation of a surface-associated protein complex
(the a-antigen of the protein C) [76] and capsular serotype
switching [77]. Also, intracellular survival in macrophages
has been demonstrated in vitro [78], by a mechanism that
presumably impairs activation of the host cell.
An offensive mode used by GBS to evade the host
immune system is its ability to induce apoptosis in
monocytes and macrophages [79]. Experimental data
suggest that apoptosis is induced by b-haemolysin/cyto-
lysin (b-h/c), a surface-associated toxin [80], although the
detailed pathogenesis that triggers apoptosis is not yet
fully understood.
Virulence
Several virulence factors have been identified in GBS,
which contribute significantly to tissue damage at the local
site of infection, as well as to a systemic inflammatory
response by the host.
The capsule, a relatively unstructured network of
high-molecular-weight polymers, is considered to be a
major virulence factor. An overwhelming majority of
GBS isolates from invasive disease are encapsulated. In
animal experiments, non-encapsulated isogenic mutants
demonstrated significantly reduced virulence compared to
the corresponding wild-type strain [81].
The already mentioned surface-associated b-h/c is a
potent, oxygen-stable, non-immunogenic GBS toxin,
comparable to streptolysin S of GAS [82]. In addition to
its hemolytic activity, b-h/c is responsible for pore for-
mation and cytolytic injury to fibroblasts, endothelial and
epithelial cells, as well as for promoting intracellular
invasion, cytokine and nitric oxide release and, conse-
quently, for triggering the sepsis cascade [80, 83]. Its
expression has therefore been correlated with the severity
of disease and tissue damage [84].
The CAMP factor has also been shown to have pore-
forming activity, but this function is mainly seen on red
blood cells pre-treated with sphingomyelinase (produced
by S. aureus) [85]. Whether this factor plays a role in
polymicrobial infections involving both GBS and S. aur-
eus has not yet been assessed.
GBS is equipped with multiple oligopeptidases that
promote the hydrolysis of several active peptides (or
their fragments), such as bradykinin, the neuropeptides
neurotensin and substance P, and adrenocorticotropin
[74]. The biological function of these pathomechanisms is
not known, but peptide degradation in the tissue sur-
roundings of GBS has been speculated in meningitis
cases.
In GAS, superantigens have been implicated as major
mediators of systemic toxicity and tissue damages. In
GBS, though, most studies have failed to demonstrate
exotoxins with superantigen activities. However, a recent
case report described a GBS toxic shock-like syndrome, in
which further experiments with human peripheral mono-
nuclear cells and the isolated strain demonstrated super-
antigenic stimulation [86]. Also, Schlievert et al. [87]
purified a protein from a GBS strain that had the bio-
logical activities of a pyrogenic toxin. Whether a hori-
zontal transfer of DNA encoding such a virulence factor is
occurring between different GBS strains, as has been
shown for GAS [88], remains to be proven; there are,
nevertheless, convincing indications for this hypothesis, in
particular for genes encoding certain GBS surface pro-
teins (a-antigen of protein C, C5a peptidase, Lmb protein)
[89]. It is therefore plausible that such a mechanism is
contributing to an increased incidence of severe diseases
[90–92].
Macrolide Resistance
The mechanisms are mainly based on efflux pumps
transporting macrolides out of the bacterial cytoplasm or
on ribosome modifications that alter the antibiotic target
site. The efflux pump is encoded by the mefA gene,
whereas the acquisition of ermB and/or ermTR (ery-
thromycin ribosome methylase) genes confers a ribo-
somal modification. erm genes are associated with
macrolide-lincosamide-streptogramin B (MLSB) resis-
tance and can be expressed constitutively (cMLSB) or
upon induction (iMLSB), although there is a heterogenic
distribution of erm genes among these phenotypes [39].
Several studies have indicated how macrolide resistance
might be acquired. A comparative pulsed-field gel elec-
trophoresis analysis showed genetic clustering among
macrolide-resistant GBS strains, with the predominance
of a single-clone family within an otherwise heteroge-
neous serotype V population [40]. Based on these data,
the emergence of a specific macrolide-resistant clone
family that possibly acquired resistance at a certain point
of evolution and then subsequently increased in numbers
was suggested. Recently, Puopolo et al. [93] found that
the ermB gene is present on the chromosome of GBS
within a transposon similar to the one identified in
Streptococcus pneumoniae, which possibly indicates the
horizontal transfer of such a mobile transposable ele-
ment among streptococci.
Clinical Manifestations
GBS may occur in a large variety of clinical manifestation,
as presented in table 2. Bacteremia without identified
source and skin and soft-tissue infections are the most
frequently reported expressions of invasive GBS disease
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in non-pregnant adults. In up to one-third of the cases, in
particular in skin and soft-tissue diseases, the pathogen is
involved in a polymicrobial infection [2, 6, 7, 11, 13, 15, 16,
94]. In such situations, S. aureus is the most frequently
isolated co-microorganism.
Skin diseases typically present as erysipelas/cellulitis,
infected wounds or ulcers. However, GBS can also cause
myositis, necrotizing fasciitis and toxic shock syndrome.
Infected Skin Ulcers
Physical defence factors and mechanical barriers are
impoverished in ulcers and wounds, facilitating the inva-
sion of GBS. Not surprisingly, the presence of decubitus
ulcers has been associated with an increased risk for
invasive GBS disease (Table 1) [11]. In patients with
diabetes mellitus and foot ulcers, apart from Staphylo-
coccus spp., GBS is the most frequently involved patho-
gen among isolated Gram-positive bacteria [95]. In
diabetic foot infections, it is important to rule out osteo-
myelitis and to distinguish between colonizing and
infecting pathogens by culturing biopsies.
Erysipelas and Cellulites
In both entities, skin lesions are frequently considered to
be a portal of entry. Cellulitis is the most reported diag-
nosis among GBS skin and soft-tissue infections (25% in
one study) [13, 47]. However, since aetiologic organisms
are only rarely isolated (positive blood cultures in 2–5%
of cases) [96, 97], the true incidence might be underesti-
mated. Thus, in patients suffering from cellulitis by an
unidentified pathogen and with known risk factors and/or
carrier status, GBS should be considered.
Necrotizing Fasciitis
This severe infection has been categorized into two
types. Type I is usually a polymicrobial infection
(including anaerobic bacteria) that is associated with
antecedent surgery, diabetes mellitus and vascular dis-
eases, and manifests clinically with destruction of fat and
fascia. Type II is monomicrobial, typically but not
exclusively caused by GAS, and occurs commonly in
patients without underlying diseases; it often presents
with severe local pain, rapidly extending necrosis of the
subcutaneous tissue and systemic toxicity. GBS as the
Table 2
Relative frequency of different clinical manifestations of
invasive GBS infections in non-pregnant adults.
Disease Median % (IQR)
Bacteremia with unknown source 24 (4–40)
Skin and soft-tissue infections 20 (12–36)
Respiratory infections 12 (3–19)
Genitourinary infections 10 (0–20)
Joint and bone infections 8 (4–19)
Abdominal infections 5 (0–10)
Endocarditis 4 (0–13)
Infections of the central nervous system 4 (0–7)
Miscellaneous < 1 (0–12)
-Intravascular-device infections




Analyses are based on 20 studies including 1167 episodes of
invasive GBS infections [2, 4, 6, 7, 9, 11, 14–17, 20, 94, 131–133,
135–139]; IQR: interquartile range
Table 3
Streptococcal toxic shock syndrome case definition.
Community-acquired case: An illness with the following clinical manifestations occurring within the first 48 hours of hospitalization
Nosocomial case: An illness with the following clinical manifestations occurring within the first 48 hours of illness
Clinical criteria:
• Hypotension : Systolic blood pressure £ 90 mmHg
• Multiorgan involvement characterized by two or more of the following:
1. Coagulopathy: Platelets £ 100,000/mm3 ( £ 100 x 106/L) or DIC
2. Renal impairment: Creatinine ‡ 2 mg/dL (‡ 177 lmol/L)
3. Liver involvement: ALAT, ASAT, total bilirubin levels ‡ twofold the upper limit of normal for the patient’s age. In patients with
preexisting liver disease, a greater than twofold increase over the baseline level
4. Lung: ARDS
5. Skin: A generalized erythematous macular rash that may desquamate
6. Soft-tissue: Necrosis, including necrotizing fasciitis or myositis, or gangrene
Laboratory criteria:
• Isolation of GAS
Diagnosis:
Probable STSS: clinical case definition + isolation of GAS from a non-sterile sitea
Confirmed STSS: clinical case definition + isolation of GAS from a normally sterile site
Adapted from CDC case definition 1996 [107].
aIn the absence of another identified aetiology for the illness; GAS: Group A Streptococcus; DIC: disseminated intravasal coagulation;
ASAT: aspartate aminotransferase; ALAT: alanine aminotransferase; ARDS: acute respiratory distress syndrome
P. Sendi et al. Invasive Group B Streptococcal Disease in Non-pregnant Adults
Infection 36 Æ 2008 Æ No. 2  URBAN & VOGEL 105
causative pathogen has been rarely reported, but the
number of cases in the literature, both in type I and II
fasciitis, is steadily increasing [7, 9, 13, 50, 90–92,
98–104]. It has been suggested that GBS necrotizing
fasciitis in non-pregnant adults tends to occur in patients
with significant underlying diseases [90], but this rela-
tionship is difficult to support by data due to the rarity of
the disease. Moreover, cases in patients without risk
factors have been reported [91, 100, 101].
Analyses of GBS serotypes and several virulence
factors in a case series have not elucidated why some
patients develop necrotizing fasciitis and others develop
both necrotizing fasciitis and toxic shock syndrome
[92]. Similarly, host genetic factors that may contribute to
the development of GBS toxic shock syndrome or necro-
tizing fasciitis are as yet undetermined. Genetic predispo-
sition has been demonstrated in invasive GAS infections:
specific haplotypes of class II human leukocyte antigens
(HLA) conferred protection against severe systemic dis-
ease, while certain haplotypes were found to be associated
with the development of necrotizing fasciitis and others
with that of toxic shock syndrome [105].
Toxic Shock Syndrome
Streptococcal toxic shock syndrome (STSS) is defined as
an acute and febrile illness that begins with mild viral
prodromi but rapidly progresses to shock and multiorgan
failure (Table 3) [106, 107]. Although STSS is classically
associated with GAS, there is an increasing recognition
that other streptococci, i.e. Groups B, C and G, can be the
causative pathogen [108–111].
Group B STSS cases are often associated with severe
skin infections [90–92, 99, 100, 112]. Comparison of the
clinical characteristics of STSS caused by GAS and GBS
in non-pregnant adults is statistically difficult, mainly be-
cause the distribution of incidence numbers is unequal.
However, there is tendency for a lower GBS frequency in
adults below 50 years of age, irrespective of the presence
of underlying disease [87, 91, 92, 100, 103].
Medical Treatment
Clinical isolates of GBS are susceptible to penicillin, the
antimicrobial agent of choice for treating these invasive
diseases [36]. In a European inter-country comparison,
the average MIC was 0.06 mg/L (broth microdilution as-
say) and 0.09 mg/L (Etest) [113]. These values are two- to
ninefold higher than those for GAS. The occurrence of
penicillin tolerance in clinical GBS isolates varies among
different studies, ranging from 5% to 15% [114]. This in
vitro phenomenon is observed when bacteria are inhibited
by low concentrations of penicillin but are killed at much
higher concentrations (MBC/MIC-ratio ‡ 1/32).
GBS strains are also susceptible to ampicillin, ceftri-
axone, cefotaxime, meropenem, levofloxacin and vanco-
mycin [36, 41]. As mentioned above, erythromycin and
clindamycin resistance is rising. Strains demonstrating
resistance to macrolides should be tested for MLSB
resistance, in particular, when considering clindamycin
treatment [115].
Aminoglycosides alone have little or no effect on
GBS, but synergistic killing with penicillin has been shown
in vitro [116]. These results have been extrapolated in
therapeutic strategies for severe sepsis cases and for iso-
lates with penicillin tolerance or with high MIC values
(e.g. > 0.1 mg/L). However, there is increasing solid evi-
dence, though more for Gram-negative than for Gram-
positive pathogens, that the addition of an aminoglycoside
to a b-lactam is not beneficial in sepsis and carries the risk
of nephrotoxicity [117]. The clinical significance of a
penicillin-aminoglycoside combination for penicillin-tol-
erant strains has not yet been established. Moreover, GBS
high-level gentamicin resistance, leading to a lack of
synergistic effect, has been also described [118]. Never-
theless, the addition of an aminoglycoside to penicillin
might be considered in selected cases.
There are no uniform treatment recommendations for
GBS skin and soft-tissue infections. Suggestions are
mostly based on case reports, case series, clinical diagnosis
or in vitro experiments. Practice guidelines published by
the IDSA give a thorough overview for the management
of skin and soft-tissue infections [119] and are likely also
applicable to those caused by GBS. Most regimens for
uncomplicated erysipelas/cellulitis include a 5- to 10-day
course of antimicrobial treatment. However, based on the
above-mentioned host risk factors for acquiring invasive
disease, the ability of the pathogen to avoid immune
clearance and the higher MICs compared to GAS, ther-
apy for 10–14 days in GBS erysipelas/cellulitis might be
considered [33]. Whether oral or intravenous therapy is
adequate, and at what time parenteral antibiotics can be
changed to oral therapy, should always be discussed.
In erysipelas, treatment with penicillin G (12–18
million units IV per day divided into four to six doses) or
with a cephalosporin (e.g. ceftriaxone 2 g IV once daily)
or vancomycin (15 mg/kg IV every 12 hours in penicillin-
allergic patients with normal renal function) is commonly
administered. Thereafter, systemic inflammatory response
signs often resolve within 1–2 days, and treatment can be
promptly switched to oral antibiotics. However, in a
Swedish study including 60 episodes of erysipelas without
previous treatment [120], oral therapy (with penicillin or
clindamycin) had no inferiority in clinical course and
outcome compared to intravenous treatment. Further-
more, penicillin V concentrations measured in punch
biopsies from 45 orally treated patients with erysipelas
exceeded the MIC of isolated streptococci [121]. Never-
theless, since penicillin MIC values of GBS are higher
than those of GAS, and macrolide and clindamycin
resistance is increasing, MIC testing can be helpful to
evaluate treatment options.
In acute cellulitis, clinical presentation may require
hospitalization and treatment with intravenous antibiotics.
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Once GBS has been identified as the causative pathogen,
antibiotic therapy should be streamlined accordingly. In
clinical practice, intravenous treatment is generally swit-
ched to oral agents after the infected area has begun to
improve (e.g. within 3–5 days). There are numerous
agents available for oral therapy, as reviewed by Jacobs
et al. [122]. Amoxicillin, among others, is effective in
treating GBS cellulitis (2–3 g per day divided into two to
three doses). Clindamycin (300 mg every 6–8 hours), or
levofloxacin (500 mg once daily) are possible alternatives
for patients with penicillin allergy.
Treatment of necrotizing fasciitis requires early and
aggressive surgical exploration (debridement of necrotic
tissue), antibiotic therapy and intensive care support. The
duration of antimicrobial treatment is generally based upon
clinical judgment [119]. In GBS necrotizing fasciitis, re-
ported treatment durations from case series include 14–21
days intravenous antibiotics, followed by 14–21 days oral
treatment [91]. As a part of the treatment concept, some
authors have advocated the use of clindamycin (600–900 mg
IV every 8 hours) in combination with penicillin (20–30
million units IV per day divided into four to six doses) in
cases of GBS necrotizing fasciitis and/or STSS [90, 91, 99].
The efficacy of clindamycin is likely related to its ability to
suppress the synthesis of GAS proteins, including M-pro-
tein and streptococcal pyrogenic exotoxins A and B [123].
Furthermore, the bactericidal effect of clindamycin is not
dependent on bacterial growth stage or inoculum size; in
contrast, these factors have been proposed as responsible
for a decreasing killing rate of GAS at higher penicillin
concentrations (‘‘Eagle effect’’) [124]. A population-based
study of invasive GAS infections reported that clindamycin
reduced mortality in patients who had necrotizing fasciitis
[125]. On the other hand, in an in vitro time-kill study using
clinically relevant antimicrobial concentrations, neither an
antagonistic nor a synergistic effect of the penicillin-clin-
damycin combination was shown [126]. However, such data
are largely lacking for GBS, and therefore recommenda-
tions for clindamycin in GAS necrotizing fasciitis cannot be
simply applied to those of GBS.
The use of intravenous immunoglobulins (IVIG) in
necrotizing fasciitis and STSS caused by GBS has not been
evaluated, even though it has been administered in anal-
ogy to Group A STSS in selected cases [90, 91, 99]. Given
the reports of a beneficial effect in STSS and in necro-
tizing fasciitis caused by GAS [127–129], together with the
identification of a purified GBS toxin isolated from a
patient suffering from STSS [86, 87], it is theoretically
plausible to regard IVIG as an adjunctive treatment.
However, no recommendation about the use of IVIG in
GBS cases can be made at this time.
Patients with relapsing skin and soft-tissue infections
and no identifiable source should be evaluated for a
prophylactic course of antibiotics or for eradication of
GBS carriage [119]. However, the most appropriate
antibiotic regimen and the efficacy of such an approach
are unknown for GBS. Options proposed for recurrent
erysipelas/cellulitis [119] may be insufficient for those
caused by GBS [48, 49, 130].
Outcome
During the last two decades, the mortality from invasive
GBS disease has declined steadily, and is currently esti-
mated at between 15–20%, with an attributable mortality
of approximately 10% [2, 4, 6, 7, 9, 14, 15, 17, 94, 131–133].
As in other bacterial diseases, critical illness, in particular
septic shock, at admission is strongly associated with in-
creased mortality. Other factors associated with mortality
include GBS bacteremia, diabetes mellitus, lung cancer,
corticosteroid therapy, chronic renal insufficiency and
congestive heart failure [7]. In GBS skin and soft-tissue
infections, advanced age, skin ulcers and polymicrobial
infections have been evaluated as risk factors for limb
amputation [13]. The mortality rate of necrotizing fasciitis
remains high, irrespective of the pathogen. In a series of
89 patients treated at a specialized center, the mortality
was still 21.3% [98]. In these infections, rapid recognition
and adequate surgical treatment have a significant influ-
ence on outcome. Group B STSS seems to have a similar
outcome to STSS caused by GAS and other pathogens,
even though the disease incidence is still too low for solid
comparative studies [92].
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